Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease

International Journal of Antimicrobial Agents

Volumn 30, Issue 5, 2007, Pages 422-427

  Conte Jr , John E ^a   Golden, Jeffrey A ^a   McIver, Marina ^a   Little, Emily ^a   Zurlinden, Elisabeth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotics; Chronic lung disease; COPD; High dose; Infection; Intrapulmonary; Levofloxacin; Lung; Pharmacodynamics; Pharmacokinetics; Respiratory

Indexed keywords

LEVOFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHOSCOPY; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; HAEMOPHILUS INFLUENZAE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG LAVAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIAE; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AREA UNDER CURVE; BLOOD CHEMICAL ANALYSIS; BRONCHITIS, CHRONIC; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHLAMYDOPHILA PNEUMONIAE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; MALE; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; OFLOXACIN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 34848850066     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.023     Document Type: Article

References (48)

1. Karlowsky J.A., Thornsberry C., Critchley I.A., et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother 47 (2003) 1790-1797
2. Jones R.N., Rubino C.M., Bhavnani S.M., and Ambrose P.G. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team. Antimicrob Agents Chemother 47 (2003) 292-296
3. Critchley I.A., Jones M.E., Heinze P.D., et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 8 (2002) 214-221
4. Jones M.E., Visser M.R., Klootwijk M., Heisig P., Verhoef J., and Schmitz F.J. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 43 (1999) 421-423
5. Flynn C.M., Johnson D.M., and Jones R.N. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains. J Chemother 8 (1996) 411-415
6. Boselli E., Breilh D., Rimmele T., et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 33 (2005) 104-109
7. File Jr. T.M., Milkovich G., Tennenberg A.M., Xiang J.X., Khashab M.M., and Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 20 (2004) 1473-1481
8. Yu V.L., Greenberg R.N., Zadeikis N., et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 125 (2004) 2135-2139
9. Dunbar L.M., Khashab M.M., Kahn J.B., Zadeikis N., Xiang J.X., and Tennenberg A.M. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 20 (2004) 555-563
10. Erard V., Lamy O., Bochud P.Y., Bille J., Cometta A., and Calandra T. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 23 (2004) 82-88
11. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., and Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189 (2004) 1590-1597
12. File Jr. T.M. A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia. Clin Cornerstone Suppl 3 (2003) S21-S28
13. Dunbar L.M., Wunderink R.G., Habib M.P., et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 37 (2003) 752-760
14. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52 (2003) 11-17
15. Hermsen E.D., Hovde L.B., Konstantinides G.N., and Rotschafer J.C. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens. Antimicrob Agents Chemother 49 (2005) 1633-1635
16. Chien S.C., Wong F.A., Fowler C.L., et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 42 (1998) 885-888
17. Piscitelli S.C., Spooner K., Baird B., et al. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 43 (1999) 2323-2327
18. Conte Jr. J.E., Golden J.A., McIver M., and Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 28 (2006) 114-121
19. Capitano B., Mattoes H.M., Shore E., et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 125 (2004) 965-973
20. Gotfried M.H., Danziger L.H., and Rodvold K.A. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119 (2001) 1114-1122
21. Rodvold K.A., Danziger L.H., and Gotfried M.H. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 47 (2003) 2450-2457
22. Drusano G.L., Preston S.L., Gotfried M.H., Danziger L.H., and Rodvold K.A. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 46 (2002) 586-589
23. Braman S.S. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 129 1 Suppl (2006) 104S-115S
24. Conte Jr. J.E., Golden J.A., Kelly M.G., and Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 25 (2005) 523-529
25. Conte Jr. J.E., Golden J.A., Kelley M.G., and Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 26 (2005) 449-456
26. Rennard S.I., Basset G., Lecossier D., et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60 (1986) 532-538
27. Baldwin D.R., Wise R., Andrews J.M., Ashby J.P., and Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 3 (1990) 886-890
28. Willcox M., Kervitsky A., Watters L.C., and King Jr. T.E. Quantification of cells recovered by bronchoalveolar lavage. Comparison of cytocentrifuge preparations with the filter method. Am Rev Respir Dis 138 (1988) 74-80
29. Sader H.S., Fritsche T.R., Mutnick A.H., and Jones R.N. Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002). Diagn Microbiol Infect Dis 47 (2003) 515-525
30. Roblin P.M., and Hammerschlag M.R. In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob Agents Chemother 47 (2003) 1447-1448
31. Duffy L.B., Crabb D.M., Bing X., and Waites K.B. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 52 (2003) 527-528
32. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents 19 (2002) 355-358
33. Hand W.L., Boozer R.M., and King-Thompson N.L. Antibiotic uptake by alveolar macrophages of smokers. Antimicrob Agents Chemother 27 (1985) 42-45
34. Conte J.E., Golden J.A., Kipps J.E., Lin E.T., and Zurlinden E. Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet 43 (2004) 395-404
35. Conte Jr. J.E., Golden J.A., Kipps J., Lin E.T., and Zurlinden E. Effects of AIDS and gender on steady-state plasma and intrapulmonary ethambutol concentrations. Antimicrob Agents Chemother 45 (2001) 2891-2896
36. Scaglione F., Mouton J.W., Mattina R., and Fraschini F. Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. Antimicrob Agents Chemother 47 (2003) 2749-2755
37. Lacy M.K., Lu W., Xu X., et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 43 (1999) 672-677
38. Nightingale C.H., Grant E.M., and Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 46 Suppl 1 (2000) 6-14
39. Mattoes H.M., Kuti J.L., Drusano G.L., and Nicolau D.P. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 26 (2004) 1187-1198
40. Drusano G.L., and Craig W.A. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 9 Suppl 3 (1997) 38-44
41. Kuti J.L., Dandekar P.K., Nightingale C.H., and Nicolau D.P. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 43 (2003) 1116-1123
42. Mouton J.W., Touzw D.J., Horrevorts A.M., and Vinks A.A. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 39 (2000) 185-201
43. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1998) 125-129
44. Rebuck J.A., Fish D.N., and Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22 (2002) 1216-1225
45. Seral C., Barcia-Macay M., Mingeot-Leclercq M.P., Tulkens P.M., and Van Bambeke F. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 55 (2005) 511-517
46. Akova M., Uzun O., Akalin H.E., Hayran M., Unal S., and Gur D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother 37 (1993) 1831-1834
47. Saltoglu N., Tasova Y., Inal A.S., Seki T., and Aksu H.S. Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J 23 (2002) 921-924
48. Alcaide F., Calatayud L., Santin M., and Martin R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob Agents Chemother 48 (2004) 4562-4565